# Myofascial Pain Syndrome and Trigger Point Management

## Definition and Epidemiology

### Myofascial Pain Syndrome (MPS)
A regional pain disorder characterized by the presence of myofascial trigger points (MTrPs). One of the most common causes of musculoskeletal pain encountered in PM&R practice. Prevalence estimates range from 30-85% of patients presenting to pain clinics. Can be primary or secondary to other conditions (radiculopathy, joint pathology, visceral disease). Affects all age groups, but most commonly diagnosed in adults aged 30-60.

### Key Characteristics
Regional rather than widespread pain (distinguishes from fibromyalgia). Referred pain patterns that are reproducible and follow predictable maps. Taut bands palpable in affected muscles. Associated motor and autonomic phenomena.

## Pathophysiology

### The Integrated Hypothesis (Simons)
Central theory explaining trigger point formation. Abnormal endplate potential activity leads to excessive acetylcholine release. Sustained sarcomere contraction creates localized energy crisis. Contracted sarcomeres compress local blood vessels, creating ischemia.

Ischemia leads to release of sensitizing substances (bradykinin, substance P, CGRP, serotonin). Sensitizing substances activate peripheral nociceptors and perpetuate the cycle. The "energy crisis" model: ATP depletion prevents calcium reuptake into sarcoplasmic reticulum.

### Central Sensitization Component
Prolonged nociceptive input from trigger points can induce central sensitization. Explains referred pain patterns, expanded receptive fields, and hyperalgesia. Dorsal horn neuroplastic changes amplify and perpetuate pain. Chronic MPS may transition from a peripheral to a centrally maintained pain state.

### Perpetuating Factors
**Mechanical**: postural dysfunction, leg length discrepancy, scoliosis, ergonomic factors. **Metabolic**: hypothyroidism, iron deficiency, vitamin D deficiency, vitamin B12 deficiency. **Psychological**: depression, anxiety, poor sleep, chronic stress. **Other**: chronic infections, visceral disease, joint hypermobility.

<image>Diagram illustrating the integrated hypothesis of myofascial trigger point pathophysiology showing the cycle of abnormal endplate activity, sustained sarcomere contraction, local ischemia, release of sensitizing substances, and nociceptor activation with feedback loops</image>

## Clinical Features of Trigger Points

### Active vs. Latent Trigger Points
**Active trigger points**: spontaneously painful, reproduce the patient's clinical complaint, refer pain in a characteristic pattern. **Latent trigger points**: palpable but not spontaneously painful; may restrict range of motion and cause weakness; can become active with stress or overuse. Both active and latent trigger points produce taut bands and local twitch responses.

| Feature | Active Trigger Point | Latent Trigger Point |
|---------|---------------------|---------------------|
| Spontaneous pain | Yes | No |
| Reproduces clinical complaint | Yes | No |
| Referred pain pattern | Present | May be elicited with compression |
| Taut band | Present | Present |
| Local twitch response | Present | Present |
| ROM restriction | Yes | Yes |
| Clinical significance | Primary pain source | May become active; contributes to dysfunction |

### Diagnostic Criteria (Simons and Travell)
**Essential criteria**: Taut band palpable in skeletal muscle. Exquisitely tender spot (trigger point) within the taut band. Patient recognition of the pain as their complaint (active trigger point).

Painful limitation of range of motion on stretch. **Confirmatory findings**: Local twitch response (LTR) on snapping palpation. Referred pain pattern consistent with known maps. Reproduction of referred pain on trigger point compression.

### Common Trigger Point Locations and Referral Patterns
**Upper trapezius**: refers to temporal region, angle of jaw, posterior neck. **Sternocleidomastoid**: refers to frontal headache, ear, periorbital region. **Levator scapulae**: refers to angle of neck and medial scapular border. **Infraspinatus**: refers to anterior shoulder and lateral arm.

**Quadratus lumborum**: refers to sacroiliac region, lower buttock, greater trochanter. **Piriformis**: refers to posterior hip, posterior thigh, can mimic sciatica. **Gluteus medius**: refers to low back, sacrum, lateral hip.

| Muscle | Trigger Point Location | Referred Pain Pattern |
|--------|----------------------|----------------------|
| Upper trapezius | Mid-muscle belly | Temporal region, angle of jaw, posterior neck |
| Sternocleidomastoid | Along muscle | Frontal headache, ear, periorbital |
| Levator scapulae | Superior angle of scapula | Angle of neck, medial scapular border |
| Infraspinatus | Infraspinous fossa | Anterior shoulder, lateral arm |
| Quadratus lumborum | Lateral to paraspinals | SI region, lower buttock, greater trochanter |
| Piriformis | Deep buttock | Posterior hip/thigh, mimics sciatica |
| Gluteus medius | Iliac crest | Low back, sacrum, lateral hip |

<image>Anatomical illustration showing common myofascial trigger point locations in the upper trapezius, levator scapulae, infraspinatus, and sternocleidomastoid muscles with their characteristic referred pain patterns mapped onto the body</image>

## Differential Diagnosis

### Fibromyalgia vs. Myofascial Pain Syndrome
Fibromyalgia: widespread pain, bilateral, above and below waist, central sensitization predominant. MPS: regional pain, identifiable trigger points with referred pain, more amenable to local treatment. The two conditions can coexist; chronic MPS may evolve into fibromyalgia. Fibromyalgia tender points are not the same as myofascial trigger points.

### Other Differential Considerations
Radiculopathy (pain follows dermatomal pattern, may have neurologic deficits). Facet arthropathy (axial pain, extension-loading exacerbates). Tendinopathy (pain at tendon insertion, provocative tests positive). Bursitis (localized swelling, point tenderness over bursa). Neuropathic pain (burning, electric quality, sensory changes in nerve distribution).

## Treatment Approaches

### Manual and Physical Therapies
**Stretching**: sustained passive stretching of the involved muscle is foundational. **Spray and stretch**: topical vapocoolant spray (ethyl chloride or fluoromethane) applied in parallel sweeps over the muscle followed by passive stretch. **Ischemic compression/myofascial release**: sustained pressure on the trigger point (60-90 seconds) until release is perceived. **Massage**: deep tissue massage, myofascial release techniques.

**Postural correction**: ergonomic assessment, workplace modifications. **Strengthening**: progressive strengthening after trigger point inactivation. **Modalities**: ultrasound, TENS, low-level laser therapy (adjunctive role).

### Dry Needling
Insertion of a solid filiform needle into the trigger point without injection of substance. Mechanism: mechanical disruption of the dysfunctional endplate, local twitch response elicitation. Eliciting a local twitch response is associated with better outcomes. Evidence supports efficacy for pain reduction and ROM improvement.

Scope of practice varies by state for physical therapists; physiatrists may perform in all states. Typically performed with acupuncture-type needles (25-30 gauge).

### Trigger Point Injection (TPI)
Injection of local anesthetic (lidocaine 0.5-1%, procaine 0.5%) into the trigger point. The mechanical effect of needling may be as important as the injectate. Technique: identify taut band, stabilize between fingers, insert needle and redirect in multiple directions seeking local twitch responses. Volume: typically 0.5-1.0 mL per trigger point.

Avoid injection into the rhomboid area (risk of pneumothorax if needle directed medially). Post-injection: stretch the muscle, apply moist heat, active range of motion.

### Injectate Options
**Local anesthetic** (lidocaine, bupivacaine): most commonly used, provides immediate pain relief. **Saline**: comparable efficacy in some studies, supporting the mechanical disruption theory. **Botulinum toxin**: reduces endplate acetylcholine release; may be useful for refractory cases but expensive and evidence is mixed. **Corticosteroid**: generally not recommended for trigger point injection; no clear advantage and risk of local tissue atrophy. **Dry needling vs. wet needling**: comparable outcomes in several studies.

### Pharmacologic Adjuncts
**NSAIDs**: may help with associated inflammation. **Muscle relaxants**: cyclobenzaprine, tizanidine (address muscle spasm component). **Low-dose tricyclic antidepressants**: amitriptyline 10-25 mg for chronic MPS with sleep disturbance. **Gabapentinoids**: if central sensitization features are present. **Topical agents**: lidocaine patches, diclofenac gel over affected area.

<image>Step-by-step illustration of trigger point injection technique showing palpation of the taut band, needle insertion with pincer grip stabilization, fanning technique in multiple directions to elicit local twitch responses, and post-injection stretching of the muscle</image>

## Addressing Perpetuating Factors

### Laboratory Screening
TSH (hypothyroidism). Iron studies (ferritin, iron, TIBC). Vitamin D level (25-hydroxyvitamin D). Vitamin B12 level. Complete metabolic panel. Consider hemoglobin A1c.

### Ergonomic and Postural Assessment
Workstation evaluation for desk workers. Leg length discrepancy assessment (heel lift if >5 mm). Sleep positioning (pillow and mattress assessment). Habitual postures (phone cradling, cross-legged sitting, purse carrying).

### Psychological Factors
Screen for depression, anxiety, and catastrophizing. Sleep hygiene optimization. Stress management strategies. Cognitive behavioral therapy referral if indicated.

## Clinical Pearls

The local twitch response during needling or injection is a favorable prognostic sign and should be actively sought. Always address perpetuating factors; without correction, trigger points will recur. Myofascial pain frequently coexists with other musculoskeletal diagnoses (rotator cuff pathology, cervical radiculopathy) and may be the primary pain generator. Upper trapezius trigger points are the most common cause of tension-type headache referral patterns.

Post-injection soreness lasting 24-72 hours is normal; advise patients in advance. Vitamin D deficiency is markedly prevalent in chronic pain populations and should be routinely checked. Consider MPS in patients with "failed" spine surgery who have persistent non-radicular pain patterns. The controversy over whether trigger points represent a distinct pathological entity should not prevent clinicians from treating patients who respond to trigger point-directed therapies.

## References

- Travell JG, Simons DG. Myofascial Pain and Dysfunction: The Trigger Point Manual. 3rd Edition. Wolters Kluwer. 2019.
- Gerwin RD. Diagnosis of Myofascial Pain Syndrome. Phys Med Rehabil Clin N Am. 2014;25(2):341-355.
- Dommerholt J, Fernandez-de-las-Penas C. Trigger Point Dry Needling: An Evidence and Clinical-Based Approach. 2nd Edition. Elsevier. 2018.
- Shah JP, et al. Myofascial Trigger Points Then and Now: A Historical and Scientific Perspective. PM&R. 2015;7(7):746-761.
- Cagnie B, et al. Evidence for the Use of Ischemic Compression and Dry Needling in the Management of Trigger Points of the Upper Trapezius in Patients with Neck Pain. Am J Phys Med Rehabil. 2015;94(7):573-583.